RT Journal Article
SR Electronic
T1 Magnetic bead-based ELISA allow inexpensive, rapid and quantitative detection of human antibodies against SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.26.20162255
DO 10.1101/2020.07.26.20162255
A1 Huergo, Luciano Fernandes
A1 Conzentino, Marcelo Santos
A1 Marques Gerhardt, Edileusa Cristina
A1 Schenberger Santos, Adrian Richard
A1 Pedrosa, Fabio Oliveira
A1 Souza, Emanuel Maltempi
A1 Nogueira, Meri Bordignon
A1 Forchhammer, Karl
A1 Moraes Rego, Fabiane Gomes
A1 Raboni, Sônia Mara
A1 Reis, Rodrigo Arantes
YR 2020
UL http://medrxiv.org/content/early/2020/07/29/2020.07.26.20162255.abstract
AB Here we describe a novel immunogenic method to detect COVID-19. The method is a chromogenic magnetic bead-based ELISA which allows inexpensive and quantitative detection of human IgG or IgM antibodies against SARS-CoV-2 in serum or whole blood samples in just 12 minutes. As a proof of concept, we compared the performance of our new method to classical ELISA. Person correlation between optical densities obtained using the two methods was 0.98, the color intensity observed in the novel method correlated with antibody titers determined by classical ELISA. The novel magnetic bead-based ELISA correctly classified all 6 positive COVID-19 samples tested and showed 100% specificity as judged by the analysis of a cohort of 26 negative samples. The magnetic bead-based ELISA performed better than classic ELISA to discriminate COVID-19 positive serum with low antibody titer. The chromogenic magnetic bead-based ELISA method described here can be applied to both point of care and high throughput analysis. The method is readily adaptable to be used with other protein and peptide-based antigens.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by UFPR, CNPq, CAPES, Fundacao Araucaria and the Alexander von Humboldt FondationAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Ethics Review Board of CHC/UFPR (n# 30578620.7.0000.0008) approved this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request